E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
‘Emergence delirium’ (ED) is described as a mental disorder during recovery from general anaesthesia. After the introduction of new inhalation anaesthetics such as sevoflurane, this phenomenon again gained prominence. The specific cause is unknown. Objective of the research
|
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary research inquiry being raised concerns anaesthesia related causes: Is it possible that adapting an amount of sevoflurane, from 1 MAC (minimum alveolar concentration) (2,5 vol%) to ½ MAC (1,25 vol%) in an MRI scan can reduce the frequency and gravity of ‘emergence delirium’?
|
|
E.2.2 | Secondary objectives of the trial |
The secondary research inquiry being raised concerns patient related causes: Are parents’ and children’s anxiety at induction, as well as their behaviour, a predictive value for the appearance of ‘ED’? In case a significant ‘ED’ appears, can this lead to an increase of behavioural disorders at 1 day, 1 week and 2 weeks after intervention?
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
b. Inclusion criteria 1. age between 1,5-6 years old 2. written permission (informed consent) 3. no premedication 4. children who have to undergo a diagnostic MRI scan 5. ASA status 1-2 6. parents who speak Dutch 7. parent present at induction
|
|
E.4 | Principal exclusion criteria |
1. cognitive or emotional development disorder (with exception of ’attention deficit hyperactivity disorder’ (ADHD)) 2. use of active ingredients (AI) which influence the central nervous system (anticonvulsants) 3. those who run the risk of developing malignant hyperthermia 4. hypersensitivity to the inhalation anaesthetic sevoflurane and to propofol 5. need for premedication
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Main study parameters/endpoints: The primary endpoints are the maximum scores on the ‘Pediatric Anesthesia Emergence Delirium Scale’ (PAED) until 1 hour after having stopped the administration of the anaesthetic. We consider a score of >10 on the PAED scale as cut-off for the presence or absence of ED. The secondary endpoints are the time between terminating the administration and the removal of the laryngeal mask airway and the time of reaction (‘responsiveness’) to light or gentle tactile stimulation. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
different doses of sevoflurane |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
After randomisation the children are divided in two groups (stratification according to age). Group A sevoflurane 1 MAC (2,5 vol.%) (13) Group B sevoflurane 0,5 MAC (1,25 vol.%) (14, 27-28) Further division in age group 1. >1,5 year old < 4 years old 2 x 10 children 2. >4 years old < 6 years old 2 x 10 children This trial will be finisched when 40 patients have been included.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |